Contract research news in brief
pharmafile | September 20, 2010 | News story | Research and Development | Covance, Galapagos, MediData Solutions, MediSync BioServices, PPD, Quotient Bioresearch, i3
A round-up of recent news from the CRO sector, featuring updates from Covance, Quotient Bioresearch, PPD, i3, Galapagos, MediSync BioServices and MediData Solutions.
Covance has opened a new central laboratory in Japan in partnership with local company BML Inc. The CB Trial Laboratory in Kawagoe City, Saitama Prefecture, will be solely used for testing clinical trial samples generated by Covance’s Japanese studies over the course of the collaboration, which is initially set at five years.
Early-stage drug development services company Quotient Bioresearch has opened a new radiochemistry facility in Cardiff, UK. The £15 million plant will be used to make custom radio-labelled compounds that support the product development needs of Quotient’s clients.
US contract research organisation PPD has expanded its own 300-bed network of phase I trial capabilities via a collaboration with a series of partner facilities, including Commonwealth Biomedical Research in Kentucky, Los Angeles-based CNS Network and Lovelace Respiratory Research, which operates sites in New Mexico, Texas, and Florida.
Eli Lilly is transferring various elements of its US clinical trials support operations to i3, marking a “significant expansion” in the relationship between the two companies, according to an i3 statement. Lilly first sought i3’s services in 2008 when it transferred the majority of its US data management operations to the clinical data services specialist.
Belgian biotech company Galapagos has bought a R&D facility in Zagreb, Croatia, from GlaxoSmithKline, and will provide research services to the former owner valued at 14 million euros over the next three years. The move includes the transfer of around 130 GSK staff to Galapagos. The Zagreb site served as GSK’s macrolide antibiotic Center of Excellence for Drug Discovery (CEDD) and before that was an R&D site for Pliva, which originally developed the blockbuster antibiotic azithromycin.
US drug delivery technology company Vyteris has merged with CRO MediSync BioServices, which provides product development, clinical trial management, and data management services. Vyteris, which develops transdermal drug products based on iontophoresis, said the aim was to provide “strategic and operational synergies and a revenue platform”.
E-clinical specialist MediData Solutions has won a new contract from Finnish drugmaker Orion for provision of its electronic data capture (EDC) and clinical data management (CDM) systems. Orion has been using the Medidata Rave system for more than three years.
Phil Taylor
Related Content
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of …
Gilead invests $5.1 billion into Galapagos NV
Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV. The collaboration …
